天臣医疗(688013) - 2025 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2025 reached ¥65,846,058.15, representing a 9.34% increase compared to ¥60,219,598.04 in the same period last year[4]. - Net profit attributable to shareholders was ¥13,186,665.95, up 16.16% from ¥11,352,005.37 year-on-year[4]. - Basic earnings per share rose to ¥0.17, reflecting a 21.43% increase from ¥0.14 in the previous year[4]. - Net profit for Q1 2025 was ¥13,186,665.95, representing a 15.9% increase from ¥11,352,005.37 in Q1 2024[17]. - The total comprehensive income for Q1 2025 was ¥13,180,346.08, compared to ¥11,402,462.19 in Q1 2024, marking an increase of 15.6%[18]. - The net profit excluding non-recurring gains and losses was ¥11,066,061.56, showing a slight increase of 0.50% from ¥11,011,201.10[4]. Cash Flow - The net cash flow from operating activities increased by 49.33%, amounting to ¥13,130,301.30, driven by higher sales revenue[4][8]. - Cash inflow from operating activities in Q1 2025 totaled ¥74,845,934.24, an increase from ¥70,383,398.75 in Q1 2024[19]. - The net cash flow from operating activities for the first quarter of 2025 was CNY 13,130,301.30, compared to CNY 8,792,670.81 in the same period of 2024, representing a year-over-year increase of approximately 49.5%[20]. - Cash flow from operating activities generated a net cash flow of CNY 5,771,734.01 in Q1 2025, down from CNY 10,914,905.91 in Q1 2024, indicating a decline of about 47.3%[28]. - The total cash outflow from operating activities was CNY 59,891,491.33 in Q1 2025, slightly up from CNY 59,423,259.89 in Q1 2024, indicating a marginal increase of 0.8%[28]. Assets and Liabilities - Total assets at the end of the reporting period were ¥658,930,471.24, a 3.40% increase from ¥637,240,337.63 at the end of the previous year[5]. - The company's current assets totaled RMB 438,095,371.63, slightly down from RMB 445,660,797.33 in the previous period[13]. - The company's total liabilities rose to RMB 87,277,308.40 from RMB 55,814,172.44, marking an increase of approximately 56.3%[14]. - The total liabilities increased to CNY 83,651,915.61 as of March 31, 2025, compared to CNY 53,138,321.15 at the end of 2024, showing a significant rise of approximately 57.2%[23]. - The total assets as of March 31, 2025, amounted to CNY 671,335,004.80, an increase from CNY 651,747,172.25 at the end of 2024, indicating a growth of approximately 3.5%[23]. Research and Development - Research and development expenses totaled ¥8,771,673.72, which is a 23.57% increase from ¥7,098,705.62, accounting for 13.32% of revenue[4][5]. - Research and development expenses for Q1 2025 were ¥8,771,673.72, up 23.6% from ¥7,098,705.62 in Q1 2024[16]. Financial Performance - The weighted average return on equity improved to 2.38%, an increase of 0.43 percentage points from 1.95%[4]. - Financial expenses for Q1 2025 showed a net income of -¥2,773,015.39, compared to -¥718,092.21 in Q1 2024, indicating a significant increase in financial efficiency[16]. - The gross profit margin for the first quarter of 2025 was approximately 57.3%, compared to 57.3% in the first quarter of 2024, indicating stable profitability[24]. Shareholder Equity - The total equity attributable to shareholders decreased by 1.68% to ¥571,653,162.84 from ¥581,426,165.19[5]. - The equity attributable to shareholders was reported at RMB 406,647,134.90, up from RMB 404,852,237.93, reflecting a modest increase[14]. Inventory and Receivables - Accounts receivable increased significantly to RMB 19,580,975.37 from RMB 12,530,351.22, representing a growth of about 56.2%[12]. - The company reported a decrease in inventory to CNY 32,802,103.60 as of March 31, 2025, down from CNY 25,325,840.31 at the end of 2024, indicating improved inventory management[22].